Trial Profile
A 10 Month Open-Label Evaluation Of The Long-Term Safety Of DVS-233 SR In Outpatients With Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- 11 Mar 2011 New trial record